Literature DB >> 1383132

Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid.

I A Rooney1, B P Morgan.   

Abstract

A functional complement system and the potential for its activation are present in human amniotic fluid. We have recently demonstrated that CD59 antigen is present and functionally active on human amniotic epithelial cells (HAEC). We have now further examined the role of this protein on HAEC and have also demonstrated its presence in amniotic fluid (AF). CD59 Ag on HAEC is similar in size to the erythrocyte protein and is anchored via glycosyl phosphatidylinositol. The AF protein retained the capacity to incorporate into target cells and protect against lysis by complement. These data suggest that HAEC secrete into AF a form of CD59 Ag which retains inhibitory activity and which may be important in protection of the foetus from maternal complement in utero.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1383132      PMCID: PMC1421564     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  18 in total

1.  Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues.

Authors:  S Meri; H Waldmann; P J Lachmann
Journal:  Lab Invest       Date:  1991-11       Impact factor: 5.662

2.  Total complement activity in maternal sera, amniotic fluids and cord sera in women with premature labor, premature rupture of membranes or chorioamnionitis.

Authors:  J Huffaker; S S Witkin; L Cutler; M L Druzin; W J Ledger
Journal:  Surg Gynecol Obstet       Date:  1989-05

3.  Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.

Authors:  S Meri; B P Morgan; A Davies; R H Daniels; M G Olavesen; H Waldmann; P J Lachmann
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

4.  Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells.

Authors:  T Hideshima; N Okada; H Okada
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

5.  Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy.

Authors:  C H Holmes; K L Simpson; S D Wainwright; C G Tate; J M Houlihan; I H Sawyer; I P Rogers; F A Spring; D J Anstee; M J Tanner
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

6.  Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo.

Authors:  M Nose; M Katoh; N Okada; M Kyogoku; H Okada
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

7.  The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells.

Authors:  I A Rooney; A Davies; D Griffiths; J D Williams; M Davies; S Meri; P J Lachmann; B P Morgan
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

8.  Protection of human amniotic epithelial cells (HAEC) from complement-mediated lysis: expression on the cells of three complement inhibitory membrane proteins.

Authors:  I A Rooney; B P Morgan
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

9.  The human cell-surface glycoproteins HuLy-m5, membrane co-factor protein (MCP) of the complement system, and trophoblast leucocyte-common (TLX) antigen, are CD46.

Authors:  D F Purcell; I F McKenzie; D M Lublin; P M Johnson; J P Atkinson; T J Oglesby; N J Deacon
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

10.  CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.

Authors:  A Davies; D L Simmons; G Hale; R A Harrison; H Tighe; P J Lachmann; H Waldmann
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  23 in total

1.  Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.

Authors:  L I Brasoveanu; E Fonsatti; A Visintin; M Pavlovic; I Cattarossi; F Colizzi; A Gasparollo; S Coral; V Horejsi; M Altomonte; M Maio
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

Review 3.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 4.  Amniotic membrane in oral and maxillofacial surgery.

Authors:  Marco Rainer Kesting; Klaus-Dietrich Wolff; Christopher Philipp Nobis; Nils Hagen Rohleder
Journal:  Oral Maxillofac Surg       Date:  2012-12-16

5.  Cytolytic complement activity in otitis media with effusion.

Authors:  M Närkiö-Mäkelä; S Meri
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

Review 6.  Complement in human reproduction: activation and control.

Authors:  I A Rooney; T J Oglesby; J P Atkinson
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 7.  Membrane proteins that protect against complement lysis.

Authors:  B P Morgan; S Meri
Journal:  Springer Semin Immunopathol       Date:  1994

8.  Shedding and enrichment of the glycolipid-anchored complement lysis inhibitor protectin (CD59) into milk fat globules.

Authors:  J Hakulinen; S Meri
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

Review 9.  A Rational Strategy for the Use of Amniotic Epithelial Stem Cell Therapy for Liver Diseases.

Authors:  Toshio Miki
Journal:  Stem Cells Transl Med       Date:  2016-03-03       Impact factor: 6.940

10.  Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).

Authors:  G A Niehans; D L Cherwitz; N A Staley; D J Knapp; A P Dalmasso
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.